Translate
Mesoblast Ltd
About
Mesoblast Ltd (AU:MSB) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Patient Recruitment Target Achieved in CLBP Pivotal Trial
Today
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
Apr 15 2026
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
Apr 10 2026
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
Apr 8 2026
Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
Recent Videos
Mesoblast Stock Analysis: The 93% Margin Commercial Pivot
Apr 22, 2026
Mesoblast Valuation: The 93% Margin the Market Is Missing
Apr 22, 2026
Mesoblast Valuation: The Overlooked 93% Margin Moat
Apr 21, 2026
Mesoblast Stock Analysis: The 93% Margin Disconnect
Apr 21, 2026
Financials
Revenue
A$65.38 M
Market Cap
A$2.92 B
EPS
-0.11